Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.24
-1.5%		$0.27
$0.18
▼
$1.45
$12.10M0.652.38 million shs2.09 million shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$6.35
-5.5%		$9.64
$5.00
▼
$26.64
$12.75M1.624,634 shs7,325 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.97
+8.2%		$0.99
$0.74
▼
$12.23
$14.80M-1.687.10 million shs4.74 million shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.20
$0.43
$0.20
▼
$1.23
$3.44M0.92808,608 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-1.54%-25.82%+1.17%-63.70%-67.58%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-5.51%-8.55%-20.23%-60.54%-73.09%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
+8.16%+19.26%-9.53%-21.30%-89.90%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%0.00%0.00%+11.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.24
-1.5%		$0.27
$0.18
▼
$1.45
$12.10M0.652.38 million shs2.09 million shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$6.35
-5.5%		$9.64
$5.00
▼
$26.64
$12.75M1.624,634 shs7,325 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.97
+8.2%		$0.99
$0.74
▼
$12.23
$14.80M-1.687.10 million shs4.74 million shs
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
$0.20
$0.43
$0.20
▼
$1.23
$3.44M0.92808,608 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-1.54%-25.82%+1.17%-63.70%-67.58%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-5.51%-8.55%-20.23%-60.54%-73.09%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
+8.16%+19.26%-9.53%-21.30%-89.90%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00%0.00%0.00%0.00%+11.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
2.80
Moderate Buy$1.33449.83% Upside
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
2.67
Moderate Buy$170.002,577.17% Upside
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest UBX, NRSN, AEON, and TPST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
Laidlaw logo
Laidlaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$1.80
9/3/2026
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
8/14/2026
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00 ➝ $1.20
7/30/2026
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/30/2026
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$1.00
7/13/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/A($4.12) per shareN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/A($0.96) per shareN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$1.35 per shareN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/A$0.39 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-$36.63M-$4.421.35N/AN/AN/AN/A-994.63%11/13/2026 (Estimated)
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$11.12M-$0.54N/AN/AN/AN/AN/AN/A12/2/2026 (Estimated)
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$4.28N/AN/AN/AN/A-576.56%-134.99%11/4/2026 (Estimated)
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%N/A

Latest UBX, NRSN, AEON, and TPST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.30-$0.34-$0.04-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/A
0.22
0.22
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A
0.31
0.31
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.38
0.38
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
N/A
1.95
1.95

Institutional Ownership

CompanyInstitutional Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
22.78%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.04%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
29.49%

Insider Ownership

CompanyInsider Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
9.40%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
27.40%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
36.20%
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
5.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
849.88 million74.37 millionNot Optionable
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
161.90 million1.38 millionNot Optionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
416.54 million10.55 millionNo Data
UNITY Biotechnology, Inc. stock logo
UBX
UNITY Biotechnology
6017.21 million16.21 millionOptionable

Recent News About These Companies

Unity Stock Crashes Nearly 50% After Nasdaq Delisting Notice
June 30, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/unity-stock-crashes-nearly-50-223255215.html
Unity Biotechnology stock plunges after Nasdaq delisting notice
June 30, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/unity-biotechnology-stock-plunges-after-nasdaq-delisting-notice-93CH-3774321
Unity Biotechnology Inc News (UBX) - Investing.com
June 26, 2025  |  investing.comhttps://www.investing.com/equities/unity-biotechnology-inc-news
UBX Unity Biotechnology, Inc. - Seeking Alpha
June 24, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/UBX
HC Wainwright & Co. Downgrades Unity Biotechnology (UBX)
May 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/hc-wainwright-co-downgrades-unity-biotechnology-ubx/ar-AA1FAA9z
Unity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho Securities
May 18, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/UBX/pressreleases/32453730/unity-biotechnology-ubx-was-downgraded-to-a-hold-rating-at-mizuho-securities/
Bay Area biotech company Unity lays off every single worker, including CEO
May 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/bay-area-biotech-company-unity-once-worth-700m-lays-off-entire-remaining-workforce/ar-AA1EdgUy
Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce
May 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/bay-area-biotech-company-unity-once-worth-700m-lays-off-entire-remaining-workforce/ar-AA1EdgUy
South San Francisco biotech company lays off entire workforce, including CEO
May 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/biotech-company-once-valued-at-700-million-slashes-entire-workforce/ar-AA1EdIpE
Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles
May 5, 2025  |  fiercebiotech.comF
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
May 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/01/3072287/0/en/unity-biotechnology-to-present-at-the-arvo-2025-annual-meeting.html
NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
April 25, 2025  |  ophthalmologytimes.comO
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
April 22, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/22/3065923/0/en/unity-biotechnology-inc-reports-first-quarter-2025-financial-results-and-business-updates.html
Unity Biotechnology price target lowered to $4 from $8 at H.C. Wainwright
March 26, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-price-target-lowered-to-4-from-8-at-h-c-wainwright-1034514135
Unity Biotechnology price target lowered to $4 from $6 at Chardan
March 26, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-price-target-lowered-to-4-from-6-at-chardan-1034514054
Unity Biotechnology announces results from ASPIRE Phase 2b study in DME
March 25, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/unity-biotechnology-announces-results-from-aspire-phase-2b-study-in-dme-1034508884
Unity reports topline outcomes from trial of diabetic macular oedema therapy
March 25, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/unity-reports-topline-outcomes-from-trial-of-diabetic-macular-oedema-therapy/ar-AA1BDWQO
UNITY Biotechnology tanks on mixed results for eye disease drug
March 25, 2025  |  thepharmaletter.comT
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
March 25, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2434950/ubx-stock-down-29-on-mixed-results-from-phase-ii-eye-disease-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2434950
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema
March 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/unity-biotechnology-shares-drop-33-153658881.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON Biopharma stock logo

AEON Biopharma NASDAQ:AEON

$0.24 0.00 (-1.54%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.25 +0.00 (+1.44%)
As of 09/18/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

NeuroSense Therapeutics stock logo

NeuroSense Therapeutics NASDAQ:NRSN

$6.35 -0.37 (-5.51%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$6.36 +0.01 (+0.08%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$0.97 +0.07 (+8.16%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$0.96 -0.01 (-1.34%)
As of 09/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

UNITY Biotechnology stock logo

UNITY Biotechnology NASDAQ:UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas